Neurogene (NGNE) Liabilities and Shareholders Equity (2013 - 2026)

Neurogene's Liabilities and Shareholders Equity history runs 14 years deep, the most recent figure standing at $263.1 million for Q1 2026.

• Quarterly Liabilities and Shareholders Equity fell 16.54% year-over-year to $263.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.1 billion (up 14.26% YoY) and the FY2025 annual result came in at $288.6 million, down 14.04% from the prior year.
• Liabilities and Shareholders Equity was $263.1 million for Q1 2026 at Neurogene, down from $288.6 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $335.7 million in Q4 2024 and bottomed at $89.6 million in Q3 2023.
• A 5-year average of $197.3 million and a median of $179.8 million in 2024 frame the typical range for Liabilities and Shareholders Equity.
• Peak annual rise in Liabilities and Shareholders Equity reached 103.7% in 2023, while the deepest fall reached 33.98% in 2023.
• Neurogene's Liabilities and Shareholders Equity stood at $109.3 million in 2022, then soared by 103.7% to $222.6 million in 2023, then surged by 50.84% to $335.7 million in 2024, then declined by 14.04% to $288.6 million in 2025, then fell by 8.82% to $263.1 million in 2026.
• Business Quant data shows NGNE's Liabilities and Shareholders Equity at $263.1 million in Q1 2026, $288.6 million in Q4 2025, and $287.8 million in Q3 2025.